Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.

Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16271. [Epub ahead of print]

PMID:
31682002
2.

Current landscape for chimeric antigen receptor T cells in lymphomas.

Skarbnik AP.

Curr Opin Hematol. 2019 Nov;26(6):421-426. doi: 10.1097/MOH.0000000000000544.

PMID:
31483334
3.

A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma.

Biran N, Rowley SD, Vesole DH, Zhang S, Donato ML, Skarbnik AP, Richter J, Pecora A, Siegel DS.

Bone Marrow Transplant. 2019 Nov;54(11):1881-1891. doi: 10.1038/s41409-019-0534-0. Epub 2019 May 17.

PMID:
31101891
4.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.

Blood Adv. 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180.

5.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR.

Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19.

PMID:
31004001
6.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.

Blood. 2018 Dec 6;132(23):2446-2455. doi: 10.1182/blood-2018-05-850461. Epub 2018 Oct 4.

7.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

8.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

9.

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.

Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Khan N, Cheson BD.

Blood Adv. 2018 Apr 10;2(7):762-768. doi: 10.1182/bloodadvances.2017015263.

10.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.

11.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

12.

Targeting indolent non-Hodgkin lymphoma.

Leslie LA, Skarbnik AP, Bejot C, Stives S, Feldman TA, Goy AH.

Expert Rev Hematol. 2017 Apr;10(4):299-313. doi: 10.1080/17474086.2017.1303374. Epub 2017 Mar 15. Review.

PMID:
28277849
13.

The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.

Skarbnik AP, Faderl S.

Ther Adv Hematol. 2017 Mar;8(3):99-105. doi: 10.1177/2040620716681749. Epub 2016 Dec 1. Review.

14.

Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.

Mato AR, Timlin C, Ujjani C, Skarbnik A, Howlett C, Banerjee R, Nabhan C, Schuster SJ.

Br J Haematol. 2018 Apr;181(2):259-261. doi: 10.1111/bjh.14540. Epub 2017 Feb 21. No abstract available.

PMID:
28220935
15.

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.

Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.

Leuk Lymphoma. 2017 Aug;58(8):1968-1972. doi: 10.1080/10428194.2016.1272688. Epub 2017 Jan 16. No abstract available.

PMID:
28092998
16.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

PMID:
27601462
17.

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

Biran N, Rowley SD, Vesole DH, Zhang S, Donato ML, Richter J, Skarbnik AP, Pecora A, Siegel DS.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2165-2171. doi: 10.1016/j.bbmt.2016.08.017. Epub 2016 Aug 31.

18.

Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.

Baker M, Wang H, Rowley SD, Cai L, Pecora AL, Skarbnik A, Vesole DH, Adler-Brecher B, Kim D, Donato ML.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2047-2055. doi: 10.1016/j.bbmt.2016.08.003. Epub 2016 Aug 10.

19.

Lenalidomide for mantle cell lymphoma.

Skarbnik AP, Goy AH.

Expert Rev Hematol. 2015 Jun;8(3):257-64. doi: 10.1586/17474086.2015.1035706. Review.

PMID:
25952533
20.

Mantle cell lymphoma: state of the art.

Skarbnik AP, Goy AH.

Clin Adv Hematol Oncol. 2015 Jan;13(1):44-55. Review.

PMID:
25679973
21.

Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.

Skarbnik AP, Burki M, Pro B.

Front Oncol. 2013 May 28;3:138. doi: 10.3389/fonc.2013.00138. eCollection 2013.

22.

Therapies for mantle cell lymphoma: current challenges and a brighter future.

Skarbnik AP, Smith MR.

Discov Med. 2013 Mar;15(82):177-87. Review.

23.

Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma.

Skarbnik AP, Pro B.

Expert Rev Hematol. 2013 Feb;6(1):1-3. doi: 10.1586/ehm.12.71. Review. No abstract available.

PMID:
23373773
24.

Does the order of factors affect the product? Lessons learned from the TORCH trial.

Skarbnik AP, Olszanski AJ.

Transl Lung Cancer Res. 2013 Feb;2(1):50-4. doi: 10.3978/j.issn.2218-6751.2012.09.09. No abstract available.

25.

Radioimmunotherapy in mantle cell lymphoma.

Skarbnik AP, Smith MR.

Best Pract Res Clin Haematol. 2012 Jun;25(2):201-10. doi: 10.1016/j.beha.2012.04.004. Epub 2012 May 9. Review.

26.

Tetanus toxoid reactive lymphadenopathy masquerading as T-cell lymphoma.

White CK, Al-Saleem T, Skarbnik AP, Smith MR.

Future Oncol. 2012 May;8(5):631-4. doi: 10.2217/fon.12.37.

PMID:
22646776
27.

Brentuximab vedotin in anaplastic large cell lymphoma.

Skarbnik AP, Smith MR.

Expert Opin Biol Ther. 2012 May;12(5):633-9. doi: 10.1517/14712598.2012.673578. Epub 2012 Mar 27.

PMID:
22449148
28.

[Desire for information and participation in therapeutic decisions concerning severe diseases, in patients of a university hospital].

Gulinelli A, Aisawa RK, Konno SN, Morinaga CV, Costardi WL, Antonio RO, Dumarco RB, Moino RM, Katz M, Giavarotti S, Skarbnik AP, Forcione CS, Chiba T, Martins MA.

Rev Assoc Med Bras (1992). 2004 Jan-Mar;50(1):41-7. Portuguese.

PMID:
15253025

Supplemental Content

Loading ...
Support Center